Summary & Overview
HCPCS Q0162: Ondansetron 1 mg Oral Anti‑emetic for Chemotherapy
HCPCS Level II code Q0162 represents ondansetron 1 mg, oral, an FDA-approved prescription anti-emetic used as a complete therapeutic substitute for an IV anti-emetic during chemotherapy, limited to a 48-hour dosing regimen. This code matters nationally because oral ondansetron administered at the time of chemotherapy can affect site-of-care choices, medication dispensing workflows, and outpatient oncology reimbursement and compliance processes. Use of Q0162 is relevant to clinicians, billing teams, pharmacy services, and payers managing supportive care for cancer patients.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical role of this medication in chemotherapy-associated nausea and vomiting, typical sites of service where the code is billed, and practical billing context. The publication summarizes common modifiers associated with outpatient drug administration, notes where input data are not available, and highlights the implications for claims submission and denial risk when an oral agent is billed as an IV substitute. The content provides benchmarking and policy-context information useful for revenue cycle, pharmacy, and oncology clinic stakeholders seeking to align coding and clinical practice with payer expectations and national billing norms.
Billing Code Overview
HCPCS Level II code Q0162 describes ondansetron 1 mg, oral, an FDA-approved prescription anti-emetic intended as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy treatment, with use limited to a 48-hour dosage regimen.
Service Type: Oral anti-emetic medication for chemotherapy-induced nausea and vomiting (CINV).
Typical Site of Service: Oncology infusion centers, outpatient oncology clinics, and other ambulatory settings where chemotherapy is administered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 56-year-old female with newly initiated moderately emetogenic intravenous chemotherapy for breast cancer receives anti-emetic prophylaxis in the outpatient infusion clinic. The oncologist prescribes oral Q0162 (ondansetron 1 mg, oral) to be given as a complete therapeutic substitute for an IV anti-emetic at the time of chemotherapy for up to 48 hours post-infusion when the patient can tolerate oral intake. The clinical workflow: pre-infusion nursing assessment documents nausea risk and prior reactions; the clinician documents the indication and orders the oral ondansetron dose to be administered in the clinic or dispensed as a take-home prescription when the patient is deemed clinically stable. Nursing documents administration time, route (oral), lot/expiry of medication if clinic-dispensed, and patient education about dosing and adverse effects. Billing and coding staff append appropriate modifiers for payment circumstance and link the claim to the chemotherapy encounter and relevant diagnosis codes for chemotherapy-induced nausea and vomiting or the underlying malignancy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW | Drug discarded/not administered | When partial vial or unit of ondansetron is discarded and reporting requires notation of wasted medication cost for certain payors |